These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

233 related articles for article (PubMed ID: 15588310)

  • 1. Expression of pS2 in prostate cancer correlates with grade and Chromogranin A expression but not with stage.
    Ather MH; Abbas F; Faruqui N; Israr M; Pervez S
    BMC Urol; 2004 Dec; 4(1):14. PubMed ID: 15588310
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neuroendocrine expression in node positive prostate cancer: correlation with systemic progression and patient survival.
    Bostwick DG; Qian J; Pacelli A; Zincke H; Blute M; Bergstralh EJ; Slezak JM; Cheng L
    J Urol; 2002 Sep; 168(3):1204-11. PubMed ID: 12187268
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Correlation of three immunohistochemically detected markers of neuroendocrine differentiation with clinical predictors of disease progression in prostate cancer.
    Ather MH; Abbas F; Faruqui N; Israr M; Pervez S
    BMC Urol; 2008 Dec; 8():21. PubMed ID: 19115997
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Differential expression of the pS2 protein in the human prostate and prostate cancer: association with premalignant changes and neuroendocrine differentiation.
    Bonkhoff H; Stein U; Welter C; Remberger K
    Hum Pathol; 1995 Aug; 26(8):824-8. PubMed ID: 7635445
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Microvessel density, p53, retinoblastoma, and chromogranin A immunohistochemistry as predictors of disease-specific survival following radical prostatectomy for carcinoma of the prostate.
    Krupski T; Petroni GR; Frierson HF; Theodorescu JU
    Urology; 2000 May; 55(5):743-9. PubMed ID: 10792093
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunohistochemical study of chromogranin A in Stage D2 prostate cancer.
    Kokubo H; Yamada Y; Nishio Y; Fukatsu H; Honda N; Nakagawa A; Saga S; Tsuzuki T; Hara K
    Urology; 2005 Jul; 66(1):135-40. PubMed ID: 15992907
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of neuroendocrine staining and androgen receptor expression in incidental prostatic adenocarcinoma: prognostic implications.
    Theodoropoulos VE; Tsigka A; Mihalopoulou A; Tsoukala V; Lazaris AC; Patsouris E; Ghikonti I
    Urology; 2005 Oct; 66(4):897-902. PubMed ID: 16230178
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Relationship between neuroendocrine features and prognostic parameters in human prostate adenocarcinoma.
    Bollito E; Berruti A; Bellina M; Mosca A; Leonardo E; Tarabuzzi R; Cappia S; Ari MM; Tampellini M; Fontana D; Gubetta L; Angeli A; Dogliotti L
    Ann Oncol; 2001; 12 Suppl 2():S159-64. PubMed ID: 11762345
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunoassay and immunohistology studies of chromogranin A as a neuroendocrine marker in patients with carcinoma of the prostate.
    Deftos LJ; Nakada S; Burton DW; di Sant'Agnese PA; Cockett AT; Abrahamsson PA
    Urology; 1996 Jul; 48(1):58-62. PubMed ID: 8693652
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The prognostic influence of neuroendocrine cells in prostate cancer: results of a long-term follow-up study with patients treated by radical prostatectomy.
    Noordzij MA; van der Kwast TH; van Steenbrugge GJ; Hop WJ; Schröder FH
    Int J Cancer; 1995 Jul; 62(3):252-8. PubMed ID: 7543077
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Metastatic conventional prostatic adenocarcinoma with diffuse chromogranin A and androgen receptor positivity.
    Roudier MP; True LD; Vessella RL; Higano CS
    J Clin Pathol; 2004 Mar; 57(3):321-3. PubMed ID: 14990610
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Neuroendocrine differentiation in stage D2 prostate cancers.
    Kamiya N; Suzuki H; Kawamura K; Imamoto T; Naya Y; Tochigi N; Kakuta Y; Yamaguchi K; Ishikura H; Ichikawa T
    Int J Urol; 2008 May; 15(5):423-8. PubMed ID: 18452460
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic significance of neuroendocrine expression in lymph node-positive prostate cancer.
    Quek ML; Daneshmand S; Rodrigo S; Cai J; Dorff TB; Groshen S; Skinner DG; Lieskovsky G; Pinski J
    Urology; 2006 Jun; 67(6):1247-52. PubMed ID: 16697447
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Role of tumor-associated macrophages in the Hexim1 and TGFβ/SMAD pathway, and their influence on progression of prostatic adenocarcinoma.
    Ok Atılgan A; Özdemir BH; Akçay EY; Ataol Demirkan Ö; Tekindal MA; Özkardeş H
    Pathol Res Pract; 2016 Feb; 212(2):83-92. PubMed ID: 26608417
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neuroendocrine differentiation in prostate cancer.
    Cerović SJ; Brajusković GR; Vukotić Maletić VD; Mićić SR
    Vojnosanit Pregl; 2004; 61(5):513-8. PubMed ID: 15551804
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical understaging in patients with prostate adenocarcinoma submitted to radical prostatectomy: predictive value of serum chromogranin A.
    Sciarra A; Voria G; Monti S; Mazzone L; Mariotti G; Pozza M; D'Eramo G; Silverio FD
    Prostate; 2004 Mar; 58(4):421-8. PubMed ID: 14968443
    [TBL] [Abstract][Full Text] [Related]  

  • 17. pS2 (TFF1) expression in prostate carcinoma: correlation with steroid receptor status.
    Abdou AG; Aiad HA; Sultan SM
    APMIS; 2008 Nov; 116(11):961-71. PubMed ID: 19132993
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Skewing towards neuroendocrine phenotype in high grade or high stage androgen-responsive primary prostate cancer.
    Puccetti L; Supuran CT; Fasolo PP; Conti E; Sebastiani G; Lacquaniti S; Mandras R; Milazzo MG; Dogliani N; De Giuli P; Fasolis G
    Eur Urol; 2005 Aug; 48(2):215-21; Discussion 221-3. PubMed ID: 15992991
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Primary carcinoid tumor of the prostate with concurrent adenocarcinoma: a case report.
    Ghannoum JE; DeLellis RA; Shin SJ
    Int J Surg Pathol; 2004 Apr; 12(2):167-70. PubMed ID: 15173926
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Chromogranin A staining as a prognostic variable in newly diagnosed Gleason score 7-10 prostate cancer treated with definitive radiotherapy.
    Krauss DJ; Amin M; Stone B; Ye H; Hayek S; Cotant M; Hafron J; Brabbins DS
    Prostate; 2014 May; 74(5):520-7. PubMed ID: 24375481
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.